TRANSFUSION COMPLICATIONS
Health and economic impact of posttransfusion hepatitis B and
cost-effectiveness analysis of expanded HBV testing protocols of
blood donors: a study focused on the European Union
Arturo Pereira
BACKGROUND: Residual risk of posttransfusion hepatitis B (PT-HB) may be reduced through implementation
of HBV NAT or the new, enhanced-sensitivity HBsAg
assays in routine donor testing. However, there are
some doubts about the cost-effectiveness of these new
safety measures, because hepatitis B acquired in adulthood is not regarded as a severe disease in western
countries.
STUDY DESIGN AND METHODS: A computer model
was designed to estimate the health outcomes and associated costs of patients with PT-HB. Results from this
model and estimations of the residual risk of HBV transmission, the risk reduction yielded by the new assays,
and their cost were used to calculate the cost-effectiveness of including the new HBsAg assays or singlesample HBV NAT in the routine screening of blood donors.
RESULTS: The model predicts that 0.97 percent of patients with PT-HB die of liver disease (54% of them due
to fulminant hepatitis). The mean loss of life expectancy
was 0.178 years per patient, and the present value of
the lifetime costs of treating PT-HB was 4160 euros per
patient. Single-donor HBV NAT or the new HBsAg assays would increase the life expectancy of blood recipients by 16 (95% CI, 8-40) or 14 (95% CI, 7-28) years,
respectively, per every 10 million donations tested. The
projected cost per life-year gained was 0.79 (95% CI,
0.15-1.85) million euros for the enhanced-sensitivity
HBsAg assays and 5.8 (95% CI, 1.9-13.1) million euros
for single-donation HBV NAT, both compared with
current HBsAg assays. If single-donation HBV NAT
is compared with the new HBsAg assays, its costeffectiveness ratio increases to 53 (95% CI, 16-127)
million euros.
CONCLUSION: PT-HB has few health or economic repercussions. Single-donation HBV NAT would provide a
small health benefit at a very high cost. Instead, in
some circumstances, the cost-effectiveness of enhanced-sensitivity HBsAg assays would be within acceptable ranges for new public health interventions.
C
ontinuous improvements of blood donor selection and testing protocols have nearly eliminated the risk of HIV or HCV transmission
through screened blood. This achievement has
turned attention back to posttransfusion hepatitis B (PTHB) since, albeit infrequent, it remains as a significant
transfusion-transmitted infection.1 Reasons for the persistence of a residual risk of HBV transmission include
blood collected within the HBsAg-negative window period of early infection2 and the existence of chronic carriers with either very low levels of HBsAg3 or mutant
forms of HBV,4 both escaping detection by the currently
available HBsAg assays. Testing blood donors for HBc
antibody is thought to detect most surface antigennegative chronic carriers,5,6 and such testing is mandatory in the United States, Japan, and other countries.
However, studies conducted in Europe, including areas
of low7,8 and moderate9,10 HBV endemicity, have shown
that routine screening of blood donors for anti-HBc
would produce a very low yield of HBsAg-negative, infectious donations at the cost of rejecting many safe donors.
Consequently, the most suitable way to further improve
the detection of HBV infectious blood donated in Europe
may be through the implementation of either HBV NAT
or the new HBsAg assays with subnanogram sensitivity
that are under development.11
ABBREVIATIONS: HCC = hepatocellular cancer; LY(s) = life
expectancy year(s); PT-HB = posttransfusion hepatitis B;
QALY(s) = quality-adjusted, discounted year(s).
From the Service of Hemotherapy and Hemostasis and Blood
Bank, Hospital Clinic, August Pi-Sunyer Memorial Institute for
Biomedical Research (IDIBAPS), Barcelona, Spain.
Address reprint requests to: Arturo Pereira, MD, PhD, Service of Hemotherapy, Hospital Clı́nic, Villarroel 170, 08036
Barcelona, Spain; e-mail: apereira@clinic.ub.es.
This work has been supported in part by Grant FIS 01/
1478 from the Ministry of Health of the Government of Spain.
Received for publication May 14, 2002; revision received
August 10, 2002, and accepted August 23, 2002.
TRANSFUSION 2003;43:192-201.
192 TRANSFUSION
Volume 43, February 2003
HEALTH AND ECONOMIC IMPACT OF PT-HB
In fact, within the past 3 years, some European
source plasma manufacturers have already implemented
pooled HBV NAT, and such testing of whole blood donations has begun in Japan and Germany.12 Implementation of HBV NAT for donated blood is being considered in
other European countries, especially if more suitable
screening assays become available or if such policy is
taken by neighboring countries or endorsed by the European Union.12 The requirement of HBV NAT on the recovered plasma that is sent to industrial fractionators
may be another force driving blood banks to implement
this assay for all donated blood. However, given the already low risk of HBV transmission and the relative benignity of this infection in adulthood,13 the benefits that
may be accrued by further expansion of the donor testing
protocols must be balanced against other health priorities, especially if it involves the implementation of costly
technologies. This is particularly true for European countries, where the predominant model of socialized health
care services implies that resources allocated to marginally increasing the safety of the blood supply have necessarily to be diverted from other areas of the health care
system.
The purpose of this work is to investigate the costs
and benefits that may derive from expansion of the current HBV testing protocols of blood donors. First, the
health and economic impact of PT-HB was estimated,
and then these results were used to predict the costeffectiveness of new technologies aimed at increasing the
detection rate of HBV infectious donations. Because the
health impact of HBV infection and the cost-effectiveness
estimates may vary across geographic areas, the present
analysis was focused on the European Union.
MATERIALS AND METHODS
Modeling PT-HB
A Monte Carlo simulation of a Markov model was designed to represent the more relevant health states and
outcomes, and the associated costs, of patients who received transfusion of HBV-infectious blood and controls
without hepatitis. Details on how such a simulation allows representation of the patients’ course of disease
have been published elsewhere.14,15 Survival curves were
derived from the simulation of 100,000 patients and controls, whereas 10 million cases and controls were simulated for estimating the aggregated health outcomes and
costs. The model was written in PowerBASIC Console
Compiler language (PowerBasic, Carmel, CA), and outputs were analyzed with computer software (Statistical
Package for Social Science [SPSS] v10, SPSS Inc. Chicago,
IL). Graphic plots and regression curves were drawn with
computer software (Prism v3.0, GraphPad Software Inc.,
San Diego, CA).
Probability distributions for the age of blood recipi-
ents at the time of transfusion were derived from a population of 11,252 patients who received transfusion in our
hospital from 1996 to 1999. Median age was 67 years, with
first and third quartiles being 52 and 76 years, respectively. Age-adjusted mortality rates were calculated from
life tables corresponding to the population of Spain in
199616 and were further adjusted to represent the mean
mortality rate across the European Union.17 Mortality
rates due to the underlying disease(s) that triggered the
transfusion were stratified by the recipient’s age according to Vamvakas and Taswell18 (Table 1). Probabilities for
acute and chronic events related to PT-HB are summarized in Table 1 and Fig. 1. It was assumed that all recipients of HBV-infectious blood develop acute hepatitis,
which is symptomatic in 70 percent cases. In the baseline
analysis, 1 percent of acute infections were assumed to
progress to fulminant hepatitis.19 Patients with fulminant
hepatitis who are younger than 60 years are considered
for liver transplant, and 50 percent of them will actually
receive a liver graft. Patients who do not receive transplantation face an 80 percent mortality risk, but survivors
have a five times lower probability of becoming chronic
carriers, compared with those without fulminant hepatitis.19,20 Transplant-related mortality and recurrence of
HBV infection were modeled according to Samuel et al.21
In the baseline analysis, it was assumed that 5 percent of adult patients become chronic HBV carriers.22
This percentage was adjusted for age at the time of transfusion, so it was 19 times higher for newborns, decreasing
progressively until achieving the adult rate at the age of
12. Progression of HBV infection in chronic carriers was
modeled according to Fig. 1. Patients begin at the state of
HBsAg-positive chronic hepatitis and HBV replication
(HBV DNA detectable in serum). From here they can
evolve to a nonreplicative state and even lose the HBsAg
and/or progress through compensated to decompensated cirrhosis and hepatocellular cancer (HCC) according to the transition probabilities showed in Fig. 1. At each
3-month cycle in the simulation, the hypothetical patient
faces the risk of dying before further progression of liver
disease, according to his or her age-adjusted mortality
rate. Transition probabilities between health states were
derived from the studies referred to in Fig. 1. Criteria for
selecting source studies included: (1) conducted in Western Europe; (2) lack of antiviral therapy, so study results
represent the infection’s natural history; (3) HBV replication based on detectable serum DNA rather than on the
HBeAg and anti-HBe system, as the latter is not an accurate marker for HBV replication in Southern Europe;23
and (4) enough information provided for calculating progression rates. The annual hazard rates for the analyzed
events were calculated per patient-year of follow-up
when enough data were provided in the article. In other
cases, the DEALE method was used to derive annual rates
from Kaplan-Meyer or cumulative probability plots.24 AnVolume 43, February 2003 TRANSFUSION 193
PEREIRA
TABLE 1. Transition probabilities between health states, health-related quality of life factors, and costs used in the
computer model of PT-HB
Short-term mortality because of underlying disease(s)18 (first/second year after transfusion)*
Age (years)
<41
41-65
>65
Probability of HBV-related events19-22*
Acute symptomatic infection
Acute fulminant hepatitis
Probability of receiving a liver graft (age <60 years)
Outcome after liver transplant
Mortality if not liver transplant
Probability of becoming chronic carrier
Progression of chronic hepatitis
Quality of life factors assigned to health states14,27,28
Baseline health
Acute symptomatic hepatitis
Acute fulminant hepatitis
Asymptomatic chronic carrier
Chronic hepatitis or compensated cirrhosis
Decompensated cirrhosis or HCC
Liver transplant
First quarter
Second to fourth quarter
Second and subsequent years
Cost associated with PT-HB complications (in year 2001 euros)29,30
Acute infection
Acute fulminant hepatitis
Liver transplant for acute fulminant hepatitis
Follow-up chronic hepatitis or compensated cirrhosis (per year)
Lamivudine treatment (100 mg/day × 52 weeks)
Conventional treatment of decompensated cirrhosis or HCC (per year)
Liver transplant for decompensated cirrhosis or HCC
Baseline
estimate
Range used in
sensitivity analyses
8/2
22/6
30/20
×0.5 to ×2.0
×0.5 to ×2.0
×0.5 to ×2.0
70
1
50
See text
80
5
(see text and Fig. 1)
0-10
0-100
0-50
1.00
0.70
0.20
1.00
0.90
0.50
0.50
0.75
0.85
(see text)
844€
10,488€
87,267€
417€
1154€
4903€
113,152€
* Data presented as percentages.
Fig. 1. Markov model of chronic PT-HB progression. Figures indicate the annual
probability of transition between health states. *Derived from the work by Fattovich et al.48 †Calculated from the results by Bortolotti et al.49 and Moreno-Otero et
al.50 ‡Derived from Fattovich et al.51 §Estimated from the results by Fattovich et
al.52 and Llovet et al.53 ¶Taken from Wong et al.28 In sensitivity analysis, the probabilities of seroconversion and clinical progression were multiplied by factors
ranging from ⴒ 0.5 to ⴒ 2.0.
194 TRANSFUSION
Volume 43, February 2003
nual rates were then transformed into
quarterly transition probabilities according to the equation p = 1 – exp
(–rate/4).25
We assumed that a 52-week course
of lamivudine (100 mg/day) was the
standard therapy for patients with
chronic hepatitis and HBV replication
and that such treatment would increase
by fourfold the transition rate to the
nonreplicative state.23 This response
will be sustained in 80 percent of cases,
but in half of them HBV replication will
recur within 2 years after stopping lamivudine.23 Because lamivudine has few
adverse effects and is usually well tolerated by patients, it was assumed that
90 percent of the eligible individuals
would actually complete the antiviral
treatment. It was also assumed that 20
percent of patients with decompensated
cirrhosis or HCC and nonreplicative
status would be eligible for liver transplant. Outcomes after liver transplant
HEALTH AND ECONOMIC IMPACT OF PT-HB
in these patients were modeled according to Teo et al.26
Persons who clear the HBV, either spontaneously or after
treatment, have a remaining life expectancy that is similar to that of controls without hepatitis. At each clinical
state, survival was adjusted by quality of life weights that
represent the most common estimates used in the specialized bibliography15,27,28 (see Table 1).
The costs of treating the hepatic complications of
HBV infection were derived from studies conducted in
Germany29 and the Netherlands,30 and they were actualized to year 2001 euros by the medical component of the
harmonized consumer price index for the European
Union.31 (Note: One euro (€) exchanges for one US dollar,
approximately. However, the cost figures used in this
study may not be fully applicable to the United States
because of differences in the purchasing power of money,
costs of labor and capital, and structure of health care
services between the European Union and the United
States.) Costs were assessed from the perspective of a
national health service and included only direct medical
costs. Indirect costs, such as those related to loss of productivity or other social expenses incurred by patients
with PT-HB, were not accounted for. Survival was calculated in unadjusted, undiscounted life expectancy years
(LYs) and also in quality-adjusted, discounted years
(QALYs). Costs and QALYs were discounted at a 3 percent
annual rate.
Variables included in the model of the clinical progression of PT-HB were highly interrelated, as occurs in
real-life patients. For instance, younger patients have
longer theoretical life expectancy and lower short-term
mortality because of underlying diseases. However, they
also have a higher probability of becoming long-term carriers and therefore of eventually progressing to end-stage
liver disease. The probability of receiving a liver transplant was also related to age at the time of liver failure,
which in turn was highly dependent on patient’s age at
transfusion. Such interrelations make univariate sensitivity analysis of the factors influencing on the health an
economic impact of PT-HB to be somewhat meaningless.
Therefore, a multivariate sensitivity analysis was conducted in which variables were allowed to change randomly between the bonds shown in Table 1 and Fig. 1.
Outputs from 1000 iterations of 100,000 cases each were
then analyzed by multivariate linear regression to identify
their independent association with input covariates. The
applicability conditions of this kind of regression analysis
were met by taking the natural logarithms of the dependent variables.
Modeling the cost-effectiveness of screening
blood donors for HBV
Outputs from the above model on the health and economic impact of PT-HB were used to calculate the costeffectiveness of further expanding the HBV testing pro-
tocols. Cost-effectiveness calculations were carried out
on a spreadsheet program (@Risk v4.0, Palisade Co.,
Newfield, NY; add-in to Excel, Microsoft Corporation,
Redmond, WA). This Excel add-in allows Monte Carlo
simulations to be performed by randomly drawing values
from user-defined probability distributions at each iteration. This allows those inputs that are estimated with
uncertainty to be represented in the cost-effectiveness
model by probability distributions. Most variables were
modeled as a triangular probability distribution. Such
distribution is defined by three parameters, minimum,
most likely, and maximum value, and allows uncertainty
to be modeled when there is not enough information
about the shape of data distribution.32 Variables for
which there was enough data were represented by the
probability distribution that best fitted the data. Probability distribution fitting was carried out with computer software (BestFit for Windows 4.0, Palisade Co.).
Variables included in the cost-effectiveness calculations were those having the highest influence on the
health and economic impact of PT-HB, as well as the best
estimates for the current residual risk of HBV transmission, the risk reduction that the newer HBsAg assays or
single-donation HBV NAT can yield, and the incremental
cost of these assays. In performing these calculations, it
was assumed that 1.65 blood components are transfused
on average from every donated unit of whole blood.15
Since the probabilities of developing acute fulminant
hepatitis or becoming chronic HBV carrier may be higher
among blood recipients than in general population (see
discussion), they were modeled as triangular distributions ranging from 1 percent to 10 percent (most likely,
5%) and from 5 percent to 15 percent (most likely, 10%),
respectively. This biased the calculations in favor of further expansion of HBV testing protocols.
The residual risk for HBV transmission through
HBsAg-negative blood varies from country to country
within the European Union. By use of the incidencewindow period model, it has been estimated at 1 in
63,000 blood donations in Italy,33 1 in 74,000 in Spain,34 1
in 180,000 in France,35 and 1 in 250,000 in Denmark,36
with large CIs. In the United Kingdom, a database review
of acute hepatitis B cases that were reported from 1991 to
1997 found only 24 in which transfusion was the most
probable route of infection,37 which means 1 case every
730,000 blood donations, approximately. In some German blood banks, where HBV DNA testing is performed
on every blood donation, HBV DNA-positive, HBsAgnegative donors are found at a rate of 1 in 214,000.38 In
Finland, it has been said that residual risk of transfusiontransmitted HBV infection would be around 1 in one million.12 Therefore, after taking into account the relative
number of units collected at each country,39 the weighted
mean residual risk of HBV transmission through HBsAgscreened blood was conservatively estimated at 1 in
Volume 43, February 2003 TRANSFUSION 195
PEREIRA
100,000 (range, 1 in 50,000 to 1 in 300,000) donations for
the whole European Union.
By analyzing seroconversion panels, it has been estimated that single-donation HBV NAT would reduce the
window period of current serologic assays by 25 to 36
days. For minipool NAT and the newer HBsAg assays, the
window period reduction has been estimated to range
from 9 to 11 days and 11 to 13 days, respectively.11 Based
on these data and the Retrovirus Epidemiology Donor
Study adjusted incidence of HBV infection in repeat donors (9.54 cases per 100,000 donor-years),2 the risk reduction afforded by the new HBV screening methods was
calculated. However, since the above calculations accounted only for the window period closing, and did not
consider the possible detection of HBsAg-negative
chronic carriers, the yield provided by each one of the
new HBV assays was increased by 3-fold, with this adjustment biasing the model in favor of implementing the
new technologies. The resulting risk reduction estimates
fitted inverse Gauss probability distributions defined by
the following parameters: = 5.3 and = 3.8 for singledonor NAT, = 3.8 and = 2.9 for the new HBsAg assays
(both compared with the current HBsAg assays), and =
1.4 and = 0.75 for single-donor NAT compared with the
newer HBsAg assays. In this kind of probability density
distribution is the mean and is a scale parameter that
determines the variance and shape of the distribution.40
This means, for instance, that single-donor NAT would
reduce by 5.3-fold (95% CI, 3.5- to 4.2-fold) the current
risk of HBV transmission (i.e., from 1 in 100,000 to 1 in
530,000, on average).
The incremental cost of the newer HBsAg assays was
estimated to range from 0 to 3 (most likely, 1.5) euros per
donation tested, as it was assumed that they will merely
replace the current assays. In estimating the cost of HBV
NAT, it was assumed that this assay will be performed on
automated platforms already testing donations for HCV
(and perhaps HIV too), so it will imply only the addition
of another marker to an already operational multiplex
system. However, since HCV NAT is not routinely performed in all blood banks within the European Union,
regulations compelling the use of HBV NAT would trigger
the acquisition or leasing of very expensive equipment in
some cases. Taking all this into account, the incremental
cost of single-sample HBV NAT was modeled as a triangular probability distribution ranging from 3 to 15 (most
likely, 6) euros per donation tested.
RESULTS
Health and economic impact of PT-HB
The predicted median survival for patients with PT-HB
and controls without hepatitis was 10.50 and 10.75 years,
respectively, with a 30-year projected survival rate of 21.9
and 22.2 percent, respectively. Survival curves for PT-HB
196 TRANSFUSION
Volume 43, February 2003
patients and controls nearly overlapped to one another.
The model predicts that 0.97 percent of patients given
HBV-infective blood will die of liver disease, 54 percent of
them because of fulminant hepatitis following acute infection (Tables 2, 3). Patients who received transfusion
with HBV-infective blood will lose a mean of 0.178 years
of life expectancy (0.174 QALYs) to complications of
hepatitis B. Tables 2 and 3 also show the frequency of
adverse outcomes in patients with PT-HB and the mean
present value of the lifetime costs of treating such outcomes. As can be seen, treatment of acute hepatitis
amounts to 90 percent of total lifetime costs.
Results of multivariate sensitivity analyses aimed at
identifying the factors and assumptions influencing PTHB outcomes and associated costs are shown in Table 4.
Covariates with the largest independent influence on the
health and economic repercussions of PT-HB were the
patient’s age at the time of transfusion, the probability of
fulminant hepatitis, and the probability of becoming
chronic carrier. Figure 2 illustrates the effect that these
factors had on either the life expectancy lost by patients
with PT-HB or the lifetime costs of treating HBV-related
complications. Factors related to the therapeutics of
hepatitis B, such as the assumed efficacy of antiviral
treatments or the availability of liver transplant for either
acute or late liver failure, had less influence on the aggregated outcomes (see Table 4).
Cost-effectiveness of further expansion of HBV
screening protocols
We analyzed the cost-effectiveness of three strategies
aimed at further reducing the residual risk of transfusiontransmitted HBV infection. The first consists of implementing the newer, enhanced-sensitivity HBsAg assays.
The second and third were based on single-donation
HBV NAT, implemented either before or after the above
HBsAg assays.
Table 5 shows the main health and economic repercussions projected for the three strategies. As can be
seen, substituting the new, more sensitive HBsAg assays
TABLE 2. Probability of adverse effects after PT-HB
Adverse effect
Fulminant hepatitis
Chronic hepatitis
Antiviral treatment
Decompensated cirrhosis
Hepatocellular cancer
Liver transplant
Death from HBV-related liver disease
Fulminant hepatitis
Decompensated cirrhosis or HCC
Complications of liver transplant
Percentage of patients
transfused with
HBV-infective blood
0.87
4.00
2.62
0.29
0.17
0.17
0.97
0.56
0.36
0.05
HEALTH AND ECONOMIC IMPACT OF PT-HB
TABLE 3. Outcomes of PT-HB
Average per patient transfused
with HBV-infective blood
Outcome
Life expectancy lost to PT-HB
LYs
QALYs
Lifetime cost of treating HBV complications (in euros)*
Acute hepatitis
Fulminant hepatitis
Follow-up chronic hepatitis and compensated cirrhosis
Conventional treatment of decompensated cirrhosis or HCC
Liver transplant
Total lifetime cost
0.178
0.174
3780
90
130
120
40
4160
* Future costs were discounted at a 3% annual rate and are rounded to the second significant figure.
TABLE 4. Multivariate sensitivity analysis of factors and assumptions influencing the health and economic impact
of PT-HB*
Mean ± SD
Dependent variables
LY lost to PT-HB (natural logarithm of years)
Lifetime cost due to PT-HB (natural logarithm of euros)
Covariates
Patient age (years)
Probability of fulminant hepatitis (%)
Probability of becoming chronic carrier (%)
Probability of liver transplant for fulminant hepatitis (%)
Probability of liver transplant for decompensated cirrhosis or HCC (%)
Proportion of patients on lamivudine (%)
Probability of relapse after lamivudine (%)
Seroconversion speed†
Clinical progression speed†
Short-term mortality due to underlying disease(s)†
Standardized  coefficients of regression to
ln (LY lost)
ln (costs)
0.01 ± 1.7
8.9 ± 0.5
49 ± 28
5±3
25 ± 15
50 ± 28
50 ± 30
50 ± 30
50 ± 29
2.1 ± 1.1
2.1 ± 1.1
1 ± 0.5
−0.83
0.25
0.14
−0.04
−0.01
ⱕ0.01
<0.01
−0.12
0.18
−0.09
−0.78
0.23
0.21
0.18
0.01
0.01
−0.02
−0.06
0.11
0.12
* Standardized  coefficients indicate how many SD will increase or decrease the dependent variable when the covariate changes 1 SD so
they are measuring the sensitivity of the dependent variable to changes of the covariates.54 The higher the absolute value of the standardized  coefficient, the stronger the sensitivity of the dependent variable to changes of the covariate. For instance, a 3% increase of
the probability of fulminant hepatitis will result in a 0.25 × 1.7 increase in the natural logarithm of the life years lost to PT-HB.
† Baseline values used in the model of PT-HB were multiplied by the indicated factor (see Table 1).
for those currently in use would be the most costeffective strategy, whereas implementation of individual
sample HBV NAT once these newer HBsAg assays were in
place would be the least efficient one. Compared with
current screening protocols, addition of single sample
HBV NAT would cost 5.8 (95% CI, 1.9-13.1) million euros
per LY gained. If it were implemented after the residual
risk of HBV transmission had already been reduced by
the new HbsAg assays, the cost-effectiveness of individual sample HBV NAT would increase to 53 (95% CI,
16-127) million euros per LY gained. Sensitivity analyses
showed that cost-effectiveness estimates significantly depended on the assumptions made for the current residual
risk for HBV transmission, the incremental cost of the
new technologies, and the risk reduction that they would
yield (see Table 5). In contrast, factors related to the
health and economic impact of PT-HB, such as the probabilities of presenting fulminant hepatitis or becoming
chronic carrier, had much less influence (standardized 
coefficients < 0.1).
DISCUSSION
In western countries, HBV infection acquired in adult life
is not regarded as a severe disease because it usually
resolves spontaneously, has low chronic carrier rate, and
only rarely has late progression to decompensated cirrhosis or HCC. For instance, long-term follow-up of US
military recruits who were accidentally infected through
vaccination in the early 1940s failed to show an excess of
liver disease compared with noninfected controls.13 Results from our model of PT-HB are consistent with this
view, since less that 1 percent of patients will eventually
die of liver disease, and the infection reduces the mean
patient life expectancy by only 2 months. These figures
are 10- and 4.5-fold smaller, respectively, than the
equivalent ones that were recently estimated for posttransfusion hepatitis C.15
It is worth noting that, in our model, fulminant hepatitis following acute infection accounted for more than
half the deaths attributable to PT-HB. Since this occurs
Volume 43, February 2003 TRANSFUSION 197
PEREIRA
Fig. 2. LYs (䊉) or quality-adjusted life years (䊊) lost and lifetime costs (䊏) incurred by patients with PT-HB according to age at
the time of transfusion and the assumed probabilities of fulminant hepatitis or chronic carrier.
early in the disease’s course, and is independent of the
typically low rate of chronic carrier or the competing risk
for mortality that represents the advanced age of many
blood recipients, fulminant hepatitis, albeit rare, emerges
from our study as the main hazard associated with PTHB. In addition, the risk of fulminant hepatitis among
blood recipients may be higher than the 1 percent figure
assumed in our baseline analysis, which was drawn from
cases of hepatitis B acquired from sources other than
198 TRANSFUSION
Volume 43, February 2003
blood transfusion.19 Risk of acute hepatic failure after
HBV infection or reactivation is increased in patients undergoing intermittent immunosuppression,22,41 as is the
case of those receiving courses of antineoplastic chemotherapy, most of whom are also under heavy transfusion
support. Immunosuppressive therapies also decrease the
ability of the immune system to eliminate the HBV after
infection,20,42 so the chronic carrier rate could be higher
in some groups of blood recipients than in cases of com-
HEALTH AND ECONOMIC IMPACT OF PT-HB
TABLE 5. Health gains, incremental cost, and cost-effectiveness ratio of strategies aimed at further decreasing the
risk of transfusion-transmitted HBV infection
Aggregated health gains and costs
(per 10-million donations tested)
Number of infections averted
LYs gained
QALYs gained
Net incremental cost (in million
euros)
Cost-effectiveness ratio (in million
euros)
Cost per LY gained
Cost per QALY gained
Cost per infection averted
Standardized  coefficients for factors
influencing on the cost per LY
gained†
Residual risk before intervention
Incremental cost per donation tested
Risk reduction yielded by the
intervention
New HBsAg assays vs.
current HBsAg assays*
Intervention vs. comparator
Single-sample HBV NAT vs.
current HBsAg assays*
56 (27-108)
14 (7-28)
16 (8-32)
10 (2-17)
61 (30-119)
16 (8-40)
18 (9-35)
80 (39-133)
7 (3-15)
2 (1-4)
2 (1-4)
80 (39-133)
0.79 (0.15-1.85)
0.70 (0.13-1.64)
0.20 (0.03-0.47)
5.8 (1.9-13.1)
5.1 (1.7-11.6)
1.5 (0.5-3.4)
53 (16-127)
47 (14-113)
14 (4-33)
0.64
0.73
−0.31
Single-sample HBV NAT vs.
new HBsAg assays*
0.72
0.64
−0.06
0.65
0.58
−0.35
* Data reported as mean (95% CI).
† See footnote of Table 4 for an explanation of the meaning of standardized  coefficients in sensitivity analysis.
munity-acquired hepatitis B. Both the increased risk of
fulminant hepatitis and the possible higher rates of
chronic carrier could confer on PT-HB a health repercussion significantly greater than that estimated in our baseline analysis. In fact, both factors ranked high, after patient’s age, in sensitivity analyses aimed at identifying
those variables having the greatest influence on the
health and economic impact of PT-HB.
The above uncertainties about the health and economic impact of PT-HB were translated into the costeffectiveness analysis of HBV screening protocols, where
they were biased in favor of increasing both impacts. The
cost-effectiveness analysis was also biased in favor of further expansion of the current screening protocols by assuming figures for both the current residual risk of transfusion-transmitted HBV infection and the projected risk
reduction yielded by the new testing protocols that were
higher than can be supported by current evidence. The
shortcomings of the incidence-window period model for
estimating the residual risk of PT-HB have been discussed elsewhere,2 and it is probable that such model
greatly overestimates the actual risk. In addition, the risk
of HBV transmission through blood given by HBsAgnegative chronic carriers seems to be very low in Europe,10,43 out of some high-risk groups that are already
screened out from donating blood.44 In contrast, the infectiousness of blood given by chronic carriers with low
HBV DNA burden has not unequivocally been established, 45 so the risk reduction achieved by singledonation HBV NAT might actually be smaller than what
was previously estimated.
Although the above biases favored further expansion
of HBV testing protocols, the resulting cost-effectiveness
estimates compared very unfavorably with those of most
medical and public health interventions.46 Only the new,
more sensitive HBsAg assays would have a costeffectiveness ratio within acceptable ranges, provided
that they are marketed at prices similar or very close to
those of current assays. In contrast, compared with the
current HBV screening protocols, single-donation NAT is
extremely costly for the expected health benefit, even after assuming that it would be performed on fully automated, multiplex platforms. The efficiency of singledonation HBV NAT would greatly worsen if it were
implemented after the current residual risk of PT-HB had
already been reduced by the new HBsAg assays. We did
not take into account the possibility that single-donation
HBV NAT would allow discontinuation of HBsAg testing.
This would decrease somewhat the incremental cost of
the new technology, thus improving the costeffectiveness projection, but the existence of HBsAgpositive carriers with very low serum levels of HBV DNA47
makes discontinuation of HBsAg testing quite improbable.
There are other factors potentially decreasing the effectiveness of the new HBV screening protocols that were
not taken into account in our analysis. The fact that many
patients on chronic transfusion support are actually immune to HBV because of selective vaccination was not
considered. We also did not take into account the effect
of blood donor vaccination on the residual risk of HBV
transmission. Years ago, many European countries
implemented routine vaccination of infants and adolescents against HBV, so as these people reach the age of
Volume 43, February 2003 TRANSFUSION 199
PEREIRA
donating blood, a marked reduction in the risk of transfusion-transmitted HBV infection can be anticipated. In
contrast, some circumstances that might increase the efficiency of the new assays were not considered either. For
instance, incorporation of immigrants from high HBV endemicity areas into the pool of blood donors might increase the number of HBsAg-negative carriers who pass
undetected through the current blood bank screening
protocols. Also not included in the model was the possibility that patients with PT-HB may transmit the virus to
other people, thereby amplifying the public health impact of this infection. Such an impact, however, is probably very low, as transfusion contributes to only a minority of the HBV infections found in the community.
It is a political goal of the European Union to achieve
a greater unity between member states regarding transfusion safety standards and regulations. If a consensus
decision must be taken on further expanding the HBV
testing protocols of blood donors, the results from the
present study support the implementation of enhancedsensitivity HBsAg assays instead of single-donation HBV
NAT. The latter would represent an unfair burden on limited health care resources that would probably be more
effective if allocated to other health priorities. For instance, individual sample HBV NAT of all blood donated
in the European Union, where around 14 million units
are collected per year,39 would save 22 LYs (25 QALYs)
counting all European blood recipients, at an annual cost
of 112 million euros. Allocating this sum of money to
programs of universal vaccination against the HBV seems
a wiser decision than expending it in preventing a few
transfusion-transmitted cases.
7. Allain JP, Reeves I, Kitchen AD, Wenham D, Williamson
LM. Feasibility and usefulness of an efficient anti-HBc
screening programme in blood donors. Transfus Med
1995;5:259-65.
8. Howell DR, Webster MH, Barbara JA. Retrospective follow-up of recipients and donors of blood donations reactive for anti-HBc or for single HCV antibodies. Transfus
Med 2000;10:265-9.
9. Tseliou P, Spiliotakara A, Dimitracopoulos GO, Christofidou M. Detection of hepatitis B virus DNA in blood
units with anti-HBc as the only positive serological
marker. Haematologia (Budapest) 2000;30:159-65.
10. Zervou EK, Dalekos GN, Boumba DS, Tsianos EV. Value
of anti-HBc screening of blood donors for prevention of
HBV infection: results of a 3-year prospective study in
Northwestern Greece. Transfusion 2001;41:652-8.
11. Biswas R, Busch M, Hsia C, et al. Comparative sensitivity of HBV NAT and HBsAg donor testing (abstract).
Transfusion 2001;41(Suppl.):8S.
12. Engelfriet CP, Reesink HW, Hernández JM, et al. International forum: implementation of donor screening for infectious agents transmitted by blood by nucleid acid
technology. Vox Sang 2002;82:87-111.
13. Seeff LB, Beebe GW, Hoofnagle JH, et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis
in the United States Army. N Engl J Med 1987;316:965-70.
14. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion
1999;39:479-8.
15. Pereira A, Sanz C. A model of the health and economic
impact of posttransfusion hepatitis C: application to costeffectiveness analysis of further expansion of HCV screening protocols. Transfusion 2000;40:1182-91.
REFERENCES
16. Statistical yearbook of Spain, 2000. Madrid: National Institute of Statistics, 2000 (CD-ROM edition).
1. Busch MP, Kleinman SHHBV. Amplified and back in the
blood safety spotlight. Transfusion 2001;41:1081-5.
17. OECD health data 2000 (CD edition). Paris, France:
2. Kleinman SH, Busch MP. The risks of transfusion-transmitted infection: direct estimation and mathematical
modelling. Best Pract Res Clin Haematol 2000;13:631-49.
3. Chemin J, Jeantet D, Kay A, Trepo C. Role of silent hepa-
18. Vamvakas EC, Taswell HF. Long-term survival after blood
titis B virus in chronic hepatitis B surface antigennegative liver disease. Antivir Res 2001;52:117-23.
4. Jongerius JM, Wester M, Cuypers HT, et al. New hepatitis
20. Schiodt FV, Atillasoy E, Shakil AO, et al. Etiology and out-
B virus mutant form in blood donor that is undetectable
in several hepatitis B surface antigen screening assays.
Transfusion 1998;38:56-9.
5. Mosley JW, Stevens CE, Aach RD, et al. Donor screening
21. Samuel D, Müller R, Alexander G, et al. Liver transplanta-
for antibody to hepatitis B core antigen and hepatitis B
virus infection in transfused recipients. Transfusion
1995;35:5-12.
6. Yotsuyanagi H, Yasuda K, Moriya K, et al. Frequent presence of HBV in the sera of HBsAg-negative, anti-HBcpositive blood donors. Transfusion 2001;41:1093-9.
200 TRANSFUSION
Volume 43, February 2003
OECD; 2000.
transfusion. Transfusion 1994;34:417-7.
19. Lee WM. Acute liver failure. N Engl J Med 1993;329:
1862-72.
come for 295 patients with acute liver failure in the
United States. Liver Transplant Surg 1999;5:29-34.
tion in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-7.
22. Lee WM. Hepatitis B virus infection. N Engl J Med
1997;337:1733-45.
23. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology
2001;34:1225-41.
24. Beck JR, Paukner SG, Gottlieb JE, et al. A convenient approximation of life expectancy (the ‘DEALE’). II. Use in
medical decision-making. Am J Med 1982;73:889-97.
HEALTH AND ECONOMIC IMPACT OF PT-HB
25. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983;3:419-58.
26. Teo EK, Han SH, Terrault N, et al. Liver transplantation in
patients with hepatitis B virus infection: outcome in Asian
versus white patients. Hepatology 2001;34:126-32.
27. Pereira A. Health and economic consequences of HCV
lookback. Transfusion 2001;41:832-9.
28. Wong JB, Koff RS, Tinè F, Pauker SG. Cost-effectiveness of
interferon-␣2b treatment for hepatitis B e antigen-positive
chronic hepatitis B. Ann Intern Med 1995;122:664-75.
29. Harbarth S, Szucs T, Berger K, Jilg W. The economic
burden of hepatitis B in Germany. Eur J Epidemiol
2000;16:173-7.
30. van Agthoven M, Metselaar HJ, Tilanus HW, et al. A comparison of the costs and effects of liver transplantation
for acute and for chronic liver failure. Transplant Int
2001;14:87-94.
31. Eurostat. Harmonised indices of consumer prices. Eurostat Yearb 2001:27.
32. Law AM, Kelton WD. Selecting input probability distributions. In: Law AM, Kelton WD, editors. Simulation modeling and analysis (3rd ed.). New York: McGraw-Hill;
2000:292-401.
33. Tosti ME, Solinas S, Prati D, et al. An estimate of the current risk of transmitting blood-borne infections through
blood transfusion in Italy. Br J Haematol 2002;117:215-9.
34. Alvarez M, Oyonarte S, Rodrı́guez PM, Hernández JM. Estimated risk of transfusion-transmitted viral infections in
Spain. Transfusion 2002;42:994-8.
35. Pillonel J, Saura C, Courouce AM. Screening of viral markers for HIV, HBV and HCV infection in blood donors in
France and residual risk of viral transmission by blood
transfusion. Eurosurveillance 1998;3:76-9.
36. Dickmeiss E, Christiansen AH, Smith E. Risk of disease
transmission via donor blood in Denmark at the turn of
the century. Ugeskr Laeger 2001;163:2628-32.
37. Soldan K, Ramsay M, Collins M. Acute hepatitis B infection associated with blood transfusion in England and
Wales, 1991-7: review of database. Br Med J 1999;318:95.
38. Schottstedt V, Tuma W, Bunger G, Lefevre H. PCR for
HBV, HCV and HIV-1 experiences and first results from a
routine screening programme in a large blood transfusion
service. Biologicals 1998;26:101-4.
39. Council of Europe. Autologous blood donation and transfusion in Europe report of the 1997 data 2000 (on-line).
Available from: URL: http://www.social.coe.int/en/qoflife/
publi/autolog.htm.
40. Evans M, Hastings N, Peacock B. Statistical distributions
(3rd ed.). New York: Wiley; 2000:114-6.
41. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E.
Severe hepatitis related to chemotherapy in hepatitis B
virus carriers with hematologic malignancies: survey in
Japan, 1987-1991. Cancer 1996;78:2210-5.
42. Liaw YF. Hepatitis viruses under immunosuppressive
agents. J Gastroenterol Hepatol 1998;13:14-20.
43. Allain JP, Hewitt PE, Tedder RS, Williamson LM. Evidence
that anti-HBc but not HBV DNA testing may prevent
some HBV transmission by transfusion. Br J Haematol
1999;107:186-95.
44. Hofer M, Joller-Jemelka HI, Grob PJ, et al. Frequent
chronic hepatitis B virus infection in HIV infected patients positive for antibody to hepatitis B core antigen
only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect
Dis 1998;17:6-13.
45. Prince AM, Lee DH, Brotman B. Infectivity from PCRpositive, HBsAg-negative, anti-HBs-positive cases of resolved hepatitis B infection. Transfusion 2001;41:329-32.
46. Graham JD, Corso PS, Morris JM, Segui-Gomez M, Weinstein MC. Evaluating the cost-effectiveness of clinical
and public health measures. Annu Rev Pub Health
1998;19:125-52.
47. Sato S, Ohhashi W, Ihara H, et al. Comparison of sensitivity of NAT using pooled donor samples for HBV and of a
serologic HBsAg. Transfusion 2001;41:1107-13.
48. Fattovich G, Brollo L, Giustina G, et al. Natural history
and prognostic factors for chronic hepatitis type B. Gut
1991;32:294-8.
49. Bortolotti F, Jara P, Crivellaro C, et al. Outcome of
chronic hepatitis B in Caucasian children during a 20year observation. J Hepatol 1998;29:184-90.
50. Moreno-Otero R, Garcı́a-Monzón C, Garcı́a-Sánchez A, et
al. Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAgpositive asymptomatic patients. Am J Gastroenterol
1991;86:560-4.
51. Fattovich G, Giustina G, Christensen E, et al. Influence of
hepatitis delta virus infection on morbidity and mortality
in compensated cirrhosis type B. Gut 2000;46:420-6.
52. Fattovich G, Giustina G, Schalm S, et al. Occurrence of
hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology
1995;21:77-82.
53. Llovet JM, Bustamante J, Castells A, et al. Natural history
of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.
Hepatology 1999;29:62-7.
54. Norusis MJ, editor. Building multiple regression models.
In: SPSS 6.1 guide to data analysis. Englewood Cliffs, NJ:
Prentice Hall; 1994:471-506.
Volume 43, February 2003 TRANSFUSION 201